Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study

Bonnie McNaughton, Jiri Frohlich, Amy Graham, Quincy-Robyn Young, Bonnie McNaughton, Jiri Frohlich, Amy Graham, Quincy-Robyn Young

Abstract

Background: There is a significant resumption of smoking following smoking cessation using varenicline. Both smoking cessation medications and counseling have been shown to increase smoking quit rates at one year. Thus, the combination of varenicline and interactive voice response (IVR) telephony followed by extended IVR may further improve smoking cessation rates at one and two years.

Methods: 101 participants were recruited from the community via newspaper advertisement. They attended a group counseling session and were given smoking information booklets from the Canadian Cancer Society. After 12 weeks of varenicline and 9 IVR calls, all participants who had quit smoking were randomized into 2 groups matched by levels of motivation and addiction as per baseline questionnaire score. The intervention group continued to receive bi-weekly IVR support for weeks 13-52. The control group no longer received IVR. The primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 ppm for weeks 12, 52 and 2 years. Data were analyzed by Fisher's exact test or Wilcoxon rank-sum test.

Results: Of the 101 participants, 44 (43%) had stopped smoking after 12 weeks of varenicline and 9 IVR calls. Of these, 23 (52%) were randomized to receive IVR calls from weeks 13 to 52.At 52 weeks, 26 (59%) participants remained smoke-free. Of the 23 with IVR, 12 (52.2%) stopped smoking compared to 14 of 21 (66.7%) without IVR. At 2 years, 40 of the 44 (90.9%) randomized participants were contacted and 24 of the 44 (54.5%) came in for testing. Fourteen (13% of the original cohort, 30% who were abstinent at 12 weeks and 53% who were abstinent at 52 weeks) remained smoke-free. Five of the 23 (21.7%) randomized to IVR and 9 of the 21 (42.9%) randomized to no IVR remained smoke-free at 2 years.

Conclusions: In this pilot study of an apparently healthy population, extended IVR did not affect abstinence rates. There was no relapse prevention benefit in offering 9 months of continued IVR to subjects who had stopped smoking after receiving 3 months of varenicline and IVR treatment.

Trial registration: ClinicalTrial.gov: NCT00832806.

Figures

Figure 1
Figure 1
Flow chart.

References

    1. Jorenby DE, Hays JT, Rigotti NA. et al.Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained- release bupropion for smoking cessation. JAMA. 2006;296:56–63. doi: 10.1001/jama.296.1.56.
    1. Gonzales D, Rennard SI, Nides M. et al.Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296:47–55. doi: 10.1001/jama.296.1.47.
    1. Galanti L. Tobacco smoking cessation management: integrating varenicline in current practice. Vasc Health Risk Manag. 2008;4(4):837–845.
    1. Regan S, Reyen M, Lockhart B, Richards A. An interactive voice response system to continue a hospital-based smoking cessation intervention after discharge. Nicotine Tob Res. 2011;01:1–6.
    1. Lieberman G, Naylor M. Interactive voice response technology for symptom monitoring and as an adjunct to the treatment of chronic pain. Transl Behav Med. 2012;2(1):93–101. doi: 10.1007/s13142-012-0115-x.
    1. Lal A, Mihalopoulos C, Wallace A, Vos T. The cost-effectivness of call-back counselling for smoking cessation. Tob Control. 2013. Epub ahead of print, PMID: 23748188 (PubMed – as supplied by publisher)
    1. Velicer WF, DiClemente CC, Prochaska JO, Brandenburg N. A decisional balance measure for assessing and predicting smoking status. J Pers Soc Psychol. 1985;48:279–1289.
    1. Stewart AL, Ware JE, Sherbourne CD, Wells KB. Psychological distress/well-being and cognitive function measures. Durham & London: Duke University Press; 1992. (Measuring functioning and well- being: the medical outcomes study approach).
    1. Miller NH, Taylor CB. Lifestyle management for patients with coronary heart disease: current issues in cardiac rehabilitation. Windsor: Human Kinetics; 1995. (Monograph No 2).
    1. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Sycamore: Sycamore Press; 1992. (Progress on behavior modification).
    1. Velicer WF, DiClemente CC, Prochaska JO, Brandenburg N. A decisional balance measure for assessing and predicting smoking status. J Pers Soc Psychol. 1985;48:1279–1289.
    1. Velicer WF, DiClemente CC, Rossi JS, Prochaska JO. Relapse situations and self-efficacy: an integrative model. Addict Behav. 1990;15:271–283. doi: 10.1016/0306-4603(90)90070-E.
    1. Nolan R, Parrot A, Irvine J, Reid G, Ramsden V, The multi-centre biofeedback reactivity trial: modifying cardiovascular reactivity to stress during the acute phase of smoking cessation. Schools of Psychology and Graduate Studies: University of Ottawa; 1999.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86:1119–27. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Young Q, Ignaszewski A, Fofonoff D, Kaan A. Stop D scale. J Cardiovasc Nurs. 2007;22:525–534. doi: 10.1097/01.JCN.0000297383.29250.14.
    1. McClelland. Human motivation. New York: Press Syndicate, University of Cambridge; 1987.
    1. Curry S, Wagner E. Evaluation of intrinsic motivation interventions with a self-help smoking cessation program. J Consult Clin Psychol. 1991;59(2):318–323.
    1. Vangeli E, Stapleton J, Smit E, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction. 2011;106(12):2110–2121. doi: 10.1111/j.1360-0443.2011.03565.x.
    1. Winkleby M, Jatulis D, Frank E, Fortmann S. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health. 1992;82(6):816–819. doi: 10.2105/AJPH.82.6.816.
    1. Reid R, Pipe A, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol. 2006;22(9):775–780. doi: 10.1016/S0828-282X(06)70294-X.
    1. Aubin H, Bobak A, Britton J, Oncken C, Billing C, Gong J, Williams K, Reeves K. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax. 2008;63(8):1–18.
    1. Hajek P, Stead L, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation (Cochrane Review) Cochrane Library. 2009;1:2–14.
    1. Stead L, Perera R, Lancaster T. Telephone counseling for smoking cessation (Cochrane Review) Cochrane Library. 2009;3:2–18.
    1. Tobacco Control Programme of Health Canada. Physicians for a smoke-free Canada. Ottawa: Canadian Community Health Survey, Ottawa, Cycle; 2005. pp. 3–1.
    1. Laaksonen M, Rahkonen O, Karvonen S. et al.Socioeconomic status and smoking. Eur J Public Health. 2005;15:262–269. doi: 10.1093/eurpub/cki115.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner